Susquehanna Portfolio Strategies
IOVA icon

Susquehanna Portfolio Strategies’s Iovance Biotherapeutics IOVA Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.39M Buy
1,055,581
+141,132
+15% +$536K 0.07% 305
2026
Q1 		$3.21M Hold
914,449
– – 0.05% 394
2025
Q4 		$2.5M Buy
914,449
+2,350
+0.3% +$5.44K 0.04% 453
2025
Q3 		$1.98M Buy
+912,099
New +$2.15M 0.03% 518

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Susquehanna Portfolio Strategies's IOVA Position: Q2 2026 in Review

Susquehanna Portfolio Strategies increased its Iovance Biotherapeutics (IOVA) stake by 15% in Q2 2026, buying an estimated $536K and bringing the position to 1,055,581 shares worth $4.39M. The position accounts for 0.07% of the portfolio, ranked #305.

Susquehanna Portfolio Strategies first reported a position in IOVA in Q3 2025 and has held it in 4 quarters since. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Susquehanna Portfolio Strategies held 1,055,581 shares of Iovance Biotherapeutics worth $4.39M as of Q2 2026.
  • Susquehanna Portfolio Strategies bought 141,132 Iovance Biotherapeutics shares in Q2 2026, an estimated $536K.
  • Iovance Biotherapeutics made up 0.07% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #305 holding.
  • Susquehanna Portfolio Strategies first reported a position in Iovance Biotherapeutics in Q3 2025 and has held it in 4 quarters since.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.